NASDAQ:ACHL

Achilles Therapeutics plc American Depositary Shares Stock Forecast, Price & News

$12.97
-0.08 (-0.61 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.79
Now: $12.97
$13.32
50-Day Range N/A
52-Week Range
$12.63
Now: $12.97
$18.95
Volume71,328 shs
Average Volume235,016 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACHL
CUSIPN/A
CIKN/A
Phone44 20 8154 4600
Employees153
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

2003rd out of 2,019 stocks

Biotechnology Industry

139th out of 145 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$12.97
-0.08 (-0.61 %)
(As of 04/13/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACHL News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Achilles Therapeutics plc American Depositary Shares (NASDAQ:ACHL) Frequently Asked Questions

What stocks does MarketBeat like better than Achilles Therapeutics plc American Depositary Shares?

Wall Street analysts have given Achilles Therapeutics plc American Depositary Shares a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Achilles Therapeutics plc American Depositary Shares wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Achilles Therapeutics plc American Depositary Shares' key executives?

Achilles Therapeutics plc American Depositary Shares' management team includes the following people:
  • Dr. Iraj Ali, CEO & Director (Age 45)
  • Dr. Karl Peggs M.D., Founder & Chief Medical Officer (Age 54)
  • Dr. Mark William Lowdell BSc, MSc, Ph.D., FRCPath, MICR, Founder (Age 58)
  • Dr. Charles Swanton, Founder (Age 49)
  • Dr. Sergio A. Quezada Ph.D., Founder & Chief Scientific Officer (Age 46)
  • Mr. Robert Coutts, Chief Financial Officer (Age 37)
  • Mr. Daniel Hood, Chief Legal Officer
  • Julia Wilson, Head of Communications
  • Mr. Tariq Ahmed, VP of People
  • Ms. Beverley Carr, Chief Bus. Officer

Who are some of Achilles Therapeutics plc American Depositary Shares' key competitors?

When did Achilles Therapeutics plc American Depositary Shares IPO?

(ACHL) raised $176 million in an IPO on Wednesday, March 31st 2021. The company issued 9,800,000 shares at $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. served as the underwriters for the IPO.

What is Achilles Therapeutics plc American Depositary Shares' stock symbol?

Achilles Therapeutics plc American Depositary Shares trades on the NASDAQ under the ticker symbol "ACHL."

When does Achilles Therapeutics plc American Depositary Shares' quiet period expire?

Achilles Therapeutics plc American Depositary Shares' quiet period expires on Monday, May 10th. Achilles Therapeutics plc American Depositary Shares had issued 9,750,000 shares in its initial public offering on March 31st. The total size of the offering was $175,500,000 based on an initial share price of $18.00. During Achilles Therapeutics plc American Depositary Shares' quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Achilles Therapeutics plc American Depositary Shares?

Shares of ACHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Achilles Therapeutics plc American Depositary Shares' stock price today?

One share of ACHL stock can currently be purchased for approximately $12.97.

How many employees does Achilles Therapeutics plc American Depositary Shares have?

Achilles Therapeutics plc American Depositary Shares employs 153 workers across the globe.

What is Achilles Therapeutics plc American Depositary Shares' official website?

The official website for Achilles Therapeutics plc American Depositary Shares is www.achillestx.com.

How can I contact Achilles Therapeutics plc American Depositary Shares?

The company can be reached via phone at 44 20 8154 4600.


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.